President Donald Trump speaks speaks on the latest developments of the coronavirus outbreak, while flanked by White House coronavirus response coordinator Debbie Birx (L), and U.S. Surgeon General Jerome Adams (R), in the James Brady Press Briefing Room at the White House March 19, 2020. (Photo by Chip Somodevilla/Getty Images)
President Donald Trump in a press conference on Thursday said the Food and Drug Administration is fast-tracking efforts to approve an antiviral therapy, best known for treating malaria, for use in coronavirus cases.
The drug, hydroxychloroquine, was developed more than a half-century ago and is approved for treating malaria, arthritis, and other ailments. Reports out of China and Italy suggest the drug may help, but there is no hard data yet.
"We're going to be able to make that drug available almost immediately," Trump said.
The FDA is working to conduct a "large, pragmatic clinical trial" quickly to confirm the drug's benefit to coronavirus patients, said Commissioner Dr. Stephen Hahn.
He also tempered the president's optimism about the still-untested solution.
"What's also important is not to provide false hope," he said. "We may have the right drug, but it might not be in the appropriate dosage form right now, and it might do more harm than good."
New antiviral therapies face a shorter and less arduous approval process than vaccines, several of which are under development with 12 to 18-month timelines.
"The therapies are something we could move on much faster potentially," Trump said.
He claimed the administration "slashed red tape" to develop new vaccines and therapies.
The president also held out on confirming whether he would invoke the Defense Production Act, which he signed on Wednesday, to mandate the production of needed medical supplies such as N95 respirators and surgical masks.
"If we find that we need something, then we will do that," he said.
Trump repeated that he was open to the federal government buying equity stakes in the airline, cruise, hospitality, and other industries hurt by the outbreak.
The press conference opened with more controversial language placing the blame squarely on China for the outbreak, despite concerns voiced about potentially exacerbating a backlash against Asian Americans.
"We continue our relentless effort to defeat the Chinese virus," Trump said.
Carlo and Baker cover the latest developments with the Omicron variant, and break down what we know and what we still don't. Plus, a relatively tame Black Friday, and more.
Jurors on Wednesday convicted the three white men charged in the death of Ahmaud Arbery, the Black man who was chased and fatally shot while running through their Georgia neighborhood in an attack that became part of the larger national reckoning on racial injustice during the summer of 2020. Trial attorney and former prosecutor Leslie Ricard Chambers joins Cheddar News' Closing Bell to discuss the verdict, possible sentencing, and more.
Kyle Rittenhouse was acquitted of all charges Friday after pleading self-defense in the deadly Kenosha shootings that became a flashpoint in the debate over guns, vigilantism and racial injustice in the U.S. Criminal Defense Attorney Anthony Tall joins Cheddar News' Closing Bell to discuss the verdict, potential judicial precedent, and more.
President Biden has announced his intent to nominate Fed chair Jerome Powell for another four-year term, with Lael Brainard serving as vice chair. This comes at a crucial time for the economy as inflation is surging, the supply chain is broken, and labor shortages are hampering businesses across the country. Sabrina Escobar, reporter for Barron's, discusses why Biden passed up the opportunity to put the central bank in the hands of a Democrat, and what challenges Powell faces in his second term.
Jill and Carlo are a bit delayed today on account of Carlo's internet not working. Better late than never, they discuss what we know about the suspect in the Christmas parade crash, closing arguments in the Arbery killing trial, and more.
Stocks began the week closing at session lows on a day when bond yields rose and President Biden decided to stick with Jerome Powell as Fed Chair. Bryan Lee, Chief Investment Officer at Blue Zone Wealth Advisors, joins Cheddar News' Closing Bell, where he breaks down the day's activity and discusses what the Fed now needs to do going forward.
President Joe Biden announced Monday he is re-nominating Federal Reserve Chairman Jerome Powell after weeks of speculation that he would choose Democrat and Fed Governor Lael Brainard to fill the role. Biden could be looking for continuity as the U.S. continues to grapple with COVID-19 and high inflation, and investors could be on the same page: markets and treasuries ticked up after the White House made the announcement. MarketWatch Senior Reporter Greg Robb joins Cheddar News' Closing Bell to discuss Powell's re-nomination, what we can expect from the Fed's December meeting, whether it will speed up its taper timeline, and more.
